In February 2021, Rigel entered into a global exclusive license agreement with Lilly for Rigel’s RIPK1 inhibitor program in all indications.
This collaboration includes the co-development and co-commercialization of Rigel’s R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. Pursuant to the collaboration, Lilly will also lead all clinical development of brain penetrating RIPK1 inhibitors in central nervous system (CNS) diseases.
Rigel received an upfront payment and is eligible for development, regulatory, and commercial milestone payments, as well as tiered royalty payments on any future net sales of any products emerging from the collaboration.
Development of R552:
- Rigel’s lead RIPK1 inhibitor, R552, has completed Phase 1 clinical trials
- The initial Phase 2a study of R552, in approximately 100 patients with moderately to severely active rheumatoid arthritis (RA), is anticipated to begin in the first half of 2023. The Phase 2a study analysis is expected by the end of 2024
Development of RIPK1 Inhibitors for CNS Diseases:
- Lilly will be solely responsible for all clinical development and commercialization of brain penetrating RIPK1 inhibitors in CNS indications